University of South Florida

Digital Commons @ University of South Florida
Pathology and Cell Biology Faculty Publications

Pathology and Cell Biology

2016

Cutaneous Human Papillomavirus Infection and Development of
Subsequent Squamous Cell Carcinoma of the Skin
Shalaka S. Hampras
Moffitt Cancer Center

Rhianna A. Reed
Moffitt Cancer Center

Spencer Bezalel
University of South Florida

Michael Cameron
University of South Florida

Basil Cherpelis
University of South Florida, bcherpel@usf.edu

See next page for additional authors
Follow this and additional works at: https://digitalcommons.usf.edu/pcb_facpub
Part of the Medical Cell Biology Commons, and the Pathology Commons

Scholar Commons Citation
Hampras, Shalaka S.; Reed, Rhianna A.; Bezalel, Spencer; Cameron, Michael; Cherpelis, Basil; Fenske, Neil;
Sondak, Vernon K.; Messina, Jane; Tommasino, Massimo; Gheit, Tarik; and Rollison, Dana E., "Cutaneous
Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin"
(2016). Pathology and Cell Biology Faculty Publications. 13.
https://digitalcommons.usf.edu/pcb_facpub/13

This Article is brought to you for free and open access by the Pathology and Cell Biology at Digital Commons @
University of South Florida. It has been accepted for inclusion in Pathology and Cell Biology Faculty Publications by
an authorized administrator of Digital Commons @ University of South Florida. For more information, please
contact scholarcommons@usf.edu.

Authors
Shalaka S. Hampras, Rhianna A. Reed, Spencer Bezalel, Michael Cameron, Basil Cherpelis, Neil Fenske,
Vernon K. Sondak, Jane Messina, Massimo Tommasino, Tarik Gheit, and Dana E. Rollison

This article is available at Digital Commons @ University of South Florida: https://digitalcommons.usf.edu/
pcb_facpub/13

Hindawi Publishing Corporation
Journal of Skin Cancer
Volume 2016, Article ID 1368103, 9 pages
http://dx.doi.org/10.1155/2016/1368103

Research Article
Cutaneous Human Papillomavirus Infection and Development
of Subsequent Squamous Cell Carcinoma of the Skin
Shalaka S. Hampras,1 Rhianna A. Reed,1 Spencer Bezalel,2
Michael Cameron,2 Basil Cherpelis,3,4 Neil Fenske,3,4 Vernon K. Sondak,5 Jane Messina,3,5,6
Massimo Tommasino,7 Tarik Gheit,7 and Dana E. Rollison1
1

Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA
University of South Florida, Morsani College of Medicine, Tampa, Florida, USA
3
Department of Dermatology, University of South Florida, College of Medicine, Tampa, FL, USA
4
Department of Cutaneous Surgery, University of South Florida, College of Medicine, Tampa, FL, USA
5
Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, Florida, USA
6
Departments of Pathology and Cell Biology, University of South Florida, College of Medicine, Tampa, FL, USA
7
Infections and Cancer Biology Group, International Agency for Research on Cancer-World Health Organization, Lyon 69372, France
2

Correspondence should be addressed to Shalaka S. Hampras; shalaka.hampras@moffitt.org
Received 25 August 2016; Revised 5 October 2016; Accepted 16 October 2016
Academic Editor: Günther Hofbauer
Copyright © 2016 Shalaka S. Hampras et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The role of cutaneous human papillomavirus (HPV) infection in the development of subsequent cutaneous squamous cell
carcinoma (SCC) is unknown. Pathologically confirmed cases of SCC (𝑛 = 150) enrolled in a previously conducted case-control
study were included in a retrospective cohort study to examine the association of cutaneous HPV at the time of SCC diagnosis with
the risk of subsequent SCC development. Data on HPV seropositivity, HPV DNA in eyebrow hairs (EB) and SCC tumors were
available from the parent study. Incidence of subsequent SCC was estimated using person-years of follow up. Cox Proportional
Hazards ratios were estimated to evaluate the associations of both, HPV seropositivity and HPV DNA positivity with subsequent
SCC. The five year cumulative incidence of subsequent SCC was 72%. Seropositivity to cutaneous HPV was not associated with the
risk of subsequent SCC (HR = 0.83, 95% CI = 0.41–1.67). Any beta HPV infection in EB was associated with reduced risk (HR =
0.30, 95% CI = 0.11–0.78) of subsequent SCC among cases who were positive for beta HPV DNA in tumor tissue. Infection with
beta HPV type 2 (HR = 0.32, 95% CI = 0.12–0.86) in EB was associated with reduced risk of subsequent SCC among HPV DNA
positive SCCs. In conclusion, beta HPV infection was inversely associated with the risk of subsequent SCC.

1. Introduction
Keratinocyte cancer (KC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), is the most
commonly diagnosed cancer in the United States [1]. While
ultraviolet radiation is an established risk factor for KC [2],
growing evidence suggests infection with cutaneous human
papillomavirus (HPV) may increase the risk of cutaneous
SCC [3–8]. We previously reported an increased risk of SCC
associated with the presence of four or more types of cutaneous HPV DNA in eyebrow hairs [3]. Serological responses

to genus beta HPV types were found to be associated with
increased risk of SCC [4]. Further, poor tanning ability was
associated with 6.9 times increased risk of SCC among those
who were seropositive to beta HPV type [5]. Collectively,
these findings suggest that cutaneous HPV may play a role
in the pathogenesis of SCC. However, it should be noted that
some previous case-control studies reporting an association
between beta HPV and SCC included only primary cases
of SCC [6, 9], while others [3, 4] did not differentiate
between primary and subsequent SCCs. Therefore, the role of
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cutaneous HPV infection in the development of subsequent
SCC is unknown.
As compared to BCCs, SCCs are more likely to be clinically aggressive with a propensity to recur and metastasize
[1, 10]. As reviewed previously, patients with metastatic SCC
have less than 20% survival rate over 10 years [1]. Varying
recurrence rates for SCC have been reported based on the
site of involvement, metastasis, and grade. In a retrospective
study, 30% SCCs involving temporal bone were found to
recur within an average of 5.8 months [11]. Others have
reported lower SCC recurrence rates of 9–15% [12, 13]. As
summarized by Alam and Ratner, risk factors for recurrence
of SCCs include tumor size, site, tumor depth, perineural
invasion, history of treatment for SCC, and tumor differentiation [1]. While these factors may aid in the identification
of SCC cases at high risk of recurrence, they provide limited
scope for intervention beyond treatment or close surveillance
to prevent the recurrence of SCC.
SCC cases are also at a high risk of developing second
primary SCCs. In a large population based study of over
25,000 Swedish SCC cases, a significantly increased risk of
second primary SCC was observed (standardized incidence
ratio = 15.6) [14]. Meta-analyses results have shown that the
risk of developing SCC subsequent to an “index” SCC was
18% [15]. As cautioned by Marcil and Stern, some of the
previous studies examining the risk of a subsequent SCC
included index SCC cases with a history of >1 SCC or did
not provide such information. Thus, the index SCCs may
have comprised both first and recurrent SCCs [15]. The high
morbidity associated with development of subsequent SCCs
warrants further research.
Given the increased risk of SCC observed in association
with cutaneous HPV infection as described above, it is
reasonable to hypothesize that patients with SCCs associated
with cutaneous HPV infection are more likely to develop
subsequent SCCs compared to patients with SCCs that are not
associated with HPV.
Using a subset of SCC cases (𝑛 = 150) from our previously
conducted study [3, 4], we conducted a retrospective cohort
study to examine the association between cutaneous HPV
infection at the time of SCC diagnosis in the parent study with
the risk of subsequent SCC. Infection with cutaneous HPV
was assessed using three biomarkers: serum antibodies to
HPV, presence of HPV DNA in eyebrow hairs, and presence
of HPV DNA in SCC tumors.

2. Materials and Methods
2.1. Study Design and Population. The study population has
been described previously [3, 4, 16]. Briefly, a clinic based
case-control study was conducted at Moffitt Cancer Center
in Tampa, Florida, in 2007–2009. Histologically confirmed
cases of SCC (𝑛 = 173) were identified through the University
of South Florida (USF) Dermatology Clinic. Both newly
diagnosed primary SCCs and cases with a prior history of
SCC were included in the case group. Controls included
patients without history of any type of cancer and who were
negative for skin cancer based on a full-body screening exam
at the time of enrollment. Of the 173 SCC cases enrolled in
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the parent case-control study, 150 SCC cases were followed
through 2014. The remaining cases either did not return to
the clinic or were only referred to USF Dermatology Clinic
for Moh’s surgery. Cases without complete follow-up were
similar in age and gender distribution to the cases with
complete follow-up. The 150 “index” SCC cases with complete
follow-up through 2014 were included in the present analyses.
Serology data on 33 cutaneous HPV types, including HPV
types in the alpha, beta, and gamma genera (𝑛 = 150), as
well as beta HPV DNA (𝑛 = 25 beta HPV types) status in
eyebrow hairs (𝑛 = 145) and SCC tumor tissue (𝑛 = 131),
at the time of enrollment of index SCC, were available from
the parent study [3, 4]. Self-reported data on demographics,
smoking, alcohol consumption, and skin cancer risk factors,
including history of blistering sunburns, sun exposure, and
tanning ability were also available from the parent study. For
the current retrospective cohort, subsequent SCC was defined
as the SCC, including recurrent and second primary SCC,
detected after the index SCC was diagnosed at the enrollment
biopsy in the parent case-control study [3, 4]. Medical charts
of index SCCs were reviewed, and data on the date of past
history of SCC prior to enrollment of an index SCC case in the
parent case-control study, date of subsequent SCC diagnosed
after the index SCC enrollment, site and tumor dimensions
of subsequent SCC, other incident keratinocyte cancers and
date of last contact or death were abstracted. All participants
provided written informed consent, and the study protocol
was approved by the Institutional Review Board at USF.
2.2. Serology. Serum samples obtained from the index SCC
cases at the time of their enrollment in the parent study were
examined for antibodies to major capsid protein L1 for 33
cutaneous HPV types including genera alpha (2, 3, 7, 10, 27,
57, and 77); beta [beta 1 (5, 8, 20, 24, 36), beta 2 (9, 15, 17,
23, 38, 107), beta 3 (49, 75, 76), beta 4 (92), and beta 5 (96)],
gamma (4, 48, 50, 65, 88, 95, 101, 103), mu (1), and nu (41). As
described previously [4], antibodies were detected using an
enzyme linked immunosorbent assay [17, 18] and fluorescent
bead-based multiplex serology [19].
2.3. HPV DNA in Eyebrow Hairs and SCC Tumor Tissue.
Measurement of HPV DNA in eyebrow hairs and freshfrozen SCC tumors has been described in detail previously
[3, 4]. Briefly, HPV DNA was extracted from eyebrow hairs
and SCC tumor tissue with the QIAGEN EZ1 DNA Tissue
Kit, and HPV genotyping was performed using a type specific
multiplex assay detecting DNA from 25 genus beta HPV types
(5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49,
75, 76, 80, 92, 93, and 96) [20, 21].
2.4. Statistical Analyses. Follow-up time was defined as the
time interval between the date of index SCC biopsy at enrollment in the parent study and date of diagnosis of subsequent
SCC or date of last contact. Five-year cumulative incidence
of subsequent SCC was estimated using person-years of
follow-up. Demographic, lifestyle factors, and skin cancer
risk factors were compared between those who developed a
subsequent SCC and those who did not, using Chi Square and
Fisher’s exact tests, as appropriate. Cox Proportional Hazards
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ratios (HR) and corresponding 95% confidence intervals
(CIs) were estimated for associations of seropositivity to
cutaneous HPV, overall and by genera, with the risk of
subsequent SCC, adjusting for age and gender. Seropositivity
to “any” HPV was defined as proportions of SCC cases that
were positive for an antibody to at least one HPV type across
all genera (overall cutaneous HPV seropositivity), within the
specific genera (genus specific seropositivity) or within specific species (species-specific seropositivity). Seropositivity to
multiple HPV infections was defined as the presence of
antibodies corresponding to ≥2 beta HPV types.
“Any” beta HPV infection in eyebrow hairs, overall and
by species, was defined as the proportion of cases who had
DNA corresponding to at least one HPV type in genus beta
or in a given species within genus beta, respectively. Multiple
HPV infections were defined as the presence of HPV DNA
corresponding to ≥2 beta HPV types. Since SCC tumors have
lower viral DNA load compared to eyebrow hairs [3], HPV
DNA status in tumors was categorized as “negative for all of
the 25 types of beta HPV DNA” or “positive for ≥1 type of
beta HPV DNA” or “positive for ≥1 species-specific beta HPV
DNA.” Cox Proportional Hazards ratios and corresponding
95% CIs were estimated for associations of beta HPV DNA
positivity, overall and by species, with the risk of subsequent
SCC, adjusting for age and gender. Associations of both beta
HPV seropositivity and beta HPV DNA positivity in eyebrow
hairs with the risk of subsequent SCC were stratified by SCC
tumor beta HPV DNA status.

3. Results and Discussion
As seen in Table 1, SCC cases included in this study were all
White, with an average age at index SCC diagnosis of 64.5
years, with 92.8% cases reporting a prior history of SCC. Of
the 150 index SCC cases, 105 (70%) were diagnosed with at
least one KC during follow-up. Ninety-one out of the 150 SCC
cases were found to have at least one subsequent SCC since
their enrollment in the previous case-control study [3, 4]. Up
to five SCC tumors per case, the majority in the head and neck
region, were detected at the time of diagnosis of subsequent
SCC. The median follow-up time was 1.15 years. The five-year
cumulative incidence of subsequent SCC was 72%.
Subsequent SCCs were detected within an average of 1
year from the date of SCC biopsy at enrollment visit. SCC
cases with a past history of SCC or BCC or both were significantly more likely to have a subsequent SCC (Table 2). None
of the other demographic or lifestyle characteristics were
associated with subsequent SCC (Table 2). Seropositivity to
cutaneous HPV infections, overall, by genera and beta HPV
species, was not associated with the risk of subsequent SCC
(Table 3).
Presence of beta HPV DNA in eyebrow hairs was not
associated with the risk of subsequent SCC, overall or by
species (Table 4). However, after stratification by tumor beta
HPV DNA, “any” beta HPV infection in eyebrow hairs was
significantly associated with 70% reduced risk of subsequent
SCC among cases who were positive for any beta HPV DNA
in tumor tissue (Table 5). Further, species-specific analyses
showed that “any” beta-2 HPV infection in eyebrow hairs was
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associated with 68% significantly reduced risk of subsequent
SCC among tumor DNA positive index SCC cases (Table 5).
Beta HPV seropositivity was not associated with subsequent
SCC after stratification by tumor beta HPV DNA status
(Table 5).
Cutaneous SCCs contribute substantial morbidity due
their tendency to recur [1] and associated high risk of development of second primary malignances of the skin and other
organs [14]. With the rising incidence of SCC [22], the
prevalence of recurrent and second primary SCCs will also
increase contributing substantially to public health burden. It
is important to identify factors predisposing to recurrent and
second primary SCCs to guide development of better follow
up protocols, characterize high risk SCCs, and inform preventive strategies aimed at reducing the morbidity associated
with subsequent SCCs.
In this retrospective cohort study, while no association
was observed between cutaneous HPV seropositivity and the
risk of subsequent SCC, a significantly inverse association was
observed between cutaneous beta HPV infection in eyebrow
hairs detected at the time of index SCC diagnosis and subsequent SCC development, among SCC cases with HPV DNA
positive index SCC tumors. These findings are in contrast
to the positive association reported between cutaneous HPV
infection, measured by HPV serology and presence of HPV in
eyebrow hairs, and SCC [3, 4]. However, our findings are consistent with findings from previous studies on mucosal HPV
infection associated cancers. Mucosal HPV infection has
been previously associated with improved survival [23–25] or
reduced rate of recurrence [26] in some cancers. For example,
in a small study of 41 cases, recurrence rate of nasopharyngeal
carcinoma was 75% in HPV tumor DNA negative patients
compared to 11% in tumor DNA positive patients [26]. Ritchie
et al. reported that HPV positive oropharyngeal cancers
had 70% significantly improved survival compared to HPV
negative cases, with significant survival benefits for men
versus women [25]. As discussed previously [25], increased
sensitivity to radiation treatment and reduced occurrence
of P53 mutations in HPV tumor positive cases have been
suggested as possible mechanisms of improved prognosis in
association with mucosal HPV infection.
In the context of cutaneous SCC, which is mainly treated
by excision, it is not clear whether the underlying mechanisms of improved prognosis of HPV positive SCCs are
similar to those suggested for prognosis of mucosal HPV
associated cancers. Cutaneous HPV infection is thought to
be involved in the initiation, but not the maintenance of SCC
[27, 28]. One explanation of the observed inverse association
between beta HPV infection and subsequent SCC could
be that beta HPV infection in index SCC tumors may be
immunogenic and could potentially stimulate host immune
response that prevents the development of subsequent SCCs.
Our findings may suggest different mechanisms driving
tumor progression in HPV DNA positive versus HPV DNA
negative SCC cases. Immunological and genetic factors that
are associated with HPV DNA negative tumors should be
explored further. Previously, we showed that, among a subset
of SCC cases included in the present study, single nucleotide
polymorphisms (SNPs) in epidermodysplasia verruciformis
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Table 1: Demographic and baseline characteristics of 150 cutaneous squamous cell carcinoma (SCC) cases.

Variable
Age in years [Mean (std)]
Gender
Male
Female
Race
White
Other
Education
≤ 12th grade
>12th grade
Skin color
Fair white
Medium white
Light brown
Skin’s reaction to first time exposure in the sun
A blistering sunburn
A sunburn without blisters
A mild sunburn that becomes a tan
A tan with no sunburn
No change in skin color
History of blistering sunburn prior to index SCC diagnosis
No
Yes
Skin’s reaction to repeated exposure in the sun
Unable to tan
It can tan if you work at it
It tans easily
Job in sun for more than 3 months at any time in life prior to the index SCC diagnosis
No
Yes
Number of moles on the entire body
None
Less than 10 moles
10–25 moles
More than 25 moles
History of smoking
Never
Ever
History of SCC
No
Yes

genes, regulating immune response against HPV, were associated with reduced risk of beta HPV DNA positive SCC
tumors [29]. These SNPs should be explored further in
association with the risk of subsequent SCC.
The findings from our study should be interpreted with
caution. A majority (92.8%) of index SCC cases had a history
of SCC prior to their enrollment in the parent case-control
study. Thus, external validity of our findings may be limited
to those cases with a past history of SCC. Cutaneous HPV

𝑛 (%)
64.4 (10.20)
100 (66.7)
50 (33.3)
134 (100.0)
0 (0)
23 (17.4)
109 (82.6)
59 (44.4)
69 (51.9)
5 (3.8)
21 (16.0)
58 (44.3)
35 (26.7)
164 (10.7)
3 (2.3)
29 (22.3)
101 (77.7)
243 (17.6)
61 (46.6)
47 (35.9)
70 (53.0)
62 (47.0)
47 (35.3)
62 (46.6)
21 (15.8)
3 (2.3)
40 (30.8)
90 (69.2)
8 (7.2)
103 (92.8)

infection status at the diagnosis of past SCCs was unknown.
Therefore, association of change in HPV infection status
over time with the risk of subsequent SCCs could not be
evaluated. HPV DNA status in subsequent SCC tumors
detected during follow-up was not measured. Due to limited
sample size, robust statistical analyses for HPV type specific
association with subsequent SCC development could not be
conducted. The subsequent SCCs detected in this study could
be recurrent SCCs, presenting at the same anatomic site as
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Table 2: Associations between baseline skin cancer risk factors and subsequent cutaneous squamous cell carcinoma (SCC).
Variable
Age [mean (STD)]
Gender
Female
Male
History of blistering sunburn prior to index SCC
diagnosis
No
Yes
Tanning ability
No
Yes
Job in sun for more than 3 months at any time in life
prior to the index SCC diagnosis
No
Yes
Smoking
Never
Ever
Alcohol
Never drinker
1 or more drinks in past 1 year
History of SCC prior to index SCC diagnosis
No
Yes
History of BCC prior to index SCC diagnosis
No
Yes
History of SCC and BCC prior to index SCC diagnosis
No
Yes
Number of HPV types in index SCC tumors
0
1
2–5
>5

1

No subsequent SCC
(𝑛 = 59)
𝑛 (%)

Subsequent SCC (𝑛 = 91)
𝑛 (%)

𝑃 value for Chi Square test

62.9 (12.4)

65.4 (8.4)

0.161

24 (40.7)
35 (59.3)

26 (28.6)
65 (71.4)

0.12

15 (28.3)
38 (71.7)

14 (18.2)
63 (81.8)

0.17

11 (21.6)
40 (78.4)

12 (15.0)
68 (85.0)

0.33

31 (59.6)
21 (40.4)

39 (48.7)
41 (51.2)

17 (32.1)
36 (67.9)

23 (29.9)
54 (70.1)

12 (23.5)
39 (76.5)

15 (18.7)
65 (81.2)

7 (15.6)
38 (84.4)

1 (1.5)
65 (98.5)

0.0072

7 (21.2)
26 (78.8)

2 (3.6)
53 (96.4)

0.012

7 (21.9)
25 (78.1)

1 (2.0)
49 (98.0)

0.0052

23 (42.6)
12 (22.2)
17 (31.5)
2 (3.7)

22 (28.6)
14 (18.2)
33 (42.9)
8 (10.4)

0.17

0.22

0.79
0.51

Student’s 𝑡-test. 2 Fisher’s exact test.

primary SCC, or second primary SCCs and the analyses
stratified by these two outcomes were not conducted due to
small sample. Conversely, combining recurrent and second
primary SCCs as one outcome may have attenuated the true
effect of HPV infection in index SCC on the development of
recurrent or second primary SCCs.
The study has several strengths. To our knowledge, this is
the first prospective study reporting an association between
cutaneous HPV infection in SCC cases and subsequent SCCs.
Of the 173 SCC cases enrolled in the parent case-control
study, 86.7% cases were included in the present analyses

highlighting complete follow-up on a large proportion of
the cases. Since 92.8% SCC cases reported a prior history
of SCC, the findings from our study may help further
prognostic stratification of these SCCs using a biomarker of
infection. These cases may represent ideal candidates to direct
infection related prevention measures due to the high morbidity associated with risk of developing subsequent SCCs
among SCCs. Based on the observed inverse association
between HPV seropositivity and risk of subsequent SCC
(Table 3), although not significant, immune response against
HPV may protect against the development of subsequent
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Table 3: Association of seropositivity to cutaneous human papillomavirus (HPV) types at the time of the diagnosis of index SCC and risk of
subsequent squamous cell carcinoma (SCC) of the skin.
Viral infection at the time of the index SCC
diagnosis
Any cutaneous 𝐻𝑃𝑉1
Seronegative to 33 cutaneous HPV types
Seropositive to ≥1 cutaneous HPV
Alpha cutaneous HPV
Seronegative to 33 cutaneous HPV types
Alpha HPV seropositive2
Alpha HPV seronegative
Alpha HPV seropositive3
Beta HPV
Seronegative to 33 cutaneous HPV types
Beta HPV seropositive2
Beta HPV seronegative
Beta HPV seropositive3
Any beta 1 𝐻𝑃𝑉4
Seronegative
Beta 1 HPV seropositive
Any beta 2 𝐻𝑃𝑉5
Seronegative
Beta 2 HPV seropositive
Multiple beta 1 𝐻𝑃𝑉6
Seronegative
Seropositive to ≥2 beta 1 HPV
Multiple beta 2 𝐻𝑃𝑉7
Seronegative
Seropositive to ≥2 beta 2 HPV
Gamma HPV
Seronegative to 33 cutaneous HPV types
Seropositive2
Gamma HPV Seronegative
Seropositive3
Mu HPV
Seronegative to 33 cutaneous HPV types
Seropositive2
Mu HPV seronegative
Seropositive3
Nu HPV
Seronegative to 33 cutaneous HPV types
Seropositive2
Nu HPV seronegative
Seropositive3
1

No subsequent SCC (𝑛 = 59)
𝑛 (%)

Subsequent SCC (𝑛 = 91)
𝑛 (%)

HR (95% CI)∗

6 (10.2)
53 (89.8)

9 (9.9)
82 (90.1)

1.00
0.83 (0.41–1.67)

6 (21.4)
22 (78.6)
37 (62.7)
22 (37.3)

9 (20.4)
35 (79.6)
56 (61.5)
35 (38.5)

1.00
0.86 (0.40–1.82)

6 (12.0)
44 (88.0)
15 (25.4)
44 (74.6)

9 (12.0)
66 (88.0)
25 (27.5)
66 (72.5)

1.00
0.80 (0.39–1.62)
1.00
0.82 (0.51–1.30)

6 (17.6)
28 (82.3)

9 (16.4)
46 (83.6)

1.00
0.77 (0.37–1.59)

6 (17.6)
28 (82.3)

9 (15.0)
51 (85.0)

1.00
0.99 (0.48–2.04)

18 (52.9)
16 (47.1)

24 (43.6)
31 (56.4)

1.00
1.06 (0.61–1.83)

18 (52.9)
16 (47.1)

25 (41.7)
35 (58.3)

1.00
0.98 (0.58–1.67)

6 (15.0)
34 (85.0)
25 (42.4)
34 (57.6)

9 (13.2)
59 (86.8)
32 (35.2)
59 (64.8)

1.00
0.93 (0.46–1.90)
1.00
1.21 (0.78–1.87)

6 (22.2)
21 (77.8)
38 (64.4)
21 (35.6)

9 (20.5)
35 (79.5)
56 (61.5)
35 (38.5)

1.00
0.78 (0.37–1.65)
1.00
1.05 (0.68–1.61)

6 (66.7)
3 (33.3)
56 (94.9)
3 (5.1)

9 (39.1)
14 (60.9)
77 (84.6)
14 (15.4)

1.00
0.96 (0.38–2.44)
1.00
1.31 (0.73–2.34)

1.04 (0.68–1.59)

Seropositivity to any cutaneous HPV (𝑛 = 33 types) versus negative to all. 2 Seropositive to at least one genus specific type versus negative to all cutaneous
(𝑛 = 33) types. 3 Seropositive to at least one genus specific HPV versus seronegative to all genus-specific HPV types. 4 Seropositive to at least one beta 1 type
versus seronegative to 33 cutaneous HPV types. 5 Seropositive to at least one beta 2 type versus seronegative to 33 cutaneous HPV types. 6 Seropositive to ≥2
beta 1 HPV types versus seronegative to all cutaneous types or positive to at least one beta 1 HPV type. 7 Seropositive to ≥2 beta 2 HPV types versus seronegative
to all cutaneous types or positive to at least one beta 2 HPV type. HR = hazards ratio, CI = confidence interval. ∗ Adjusted for age and gender.
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Table 4: Association between cutaneous human papillomavirus (HPV) infection in eyebrow hair and the risk of subsequent squamous cell
carcinoma (SCC).
Eyebrow hair viral infection
at the index SCC diagnosis
Any beta 𝐻𝑃𝑉1
DNA negative
DNA positive
Any beta 1 𝐻𝑃𝑉2
DNA negative
DNA positive
Any beta 2 𝐻𝑃𝑉3
DNA negative
DNA positive
Multiple beta 1 𝐻𝑃𝑉4
DNA negative
DNA positive
Multiple beta 2 𝐻𝑃𝑉5
DNA negative
DNA positive

∗

No subsequent SCC (𝑛 = 59)

Subsequent SCC (𝑛 = 91)

6 (10.5)
51 (89.5)

12 (13.6)
76 (86.4)

1.00
0.84 (0.45–1.56)

6 (13.6)
38 (86.4)

12 (16.2)
62 (83.8)

1.00
0.84 (0.44–1.58)

6 (12.0)
44 (88.0)

12 (16.2)
62 (83.8)

1.00
0.85 (0.45–1.59)

25 (56.8)
19 (43.2)

37 (50.0)
37 (50.0)

1.00
1.18 (0.72–1.93)

29 (58.0)
21 (42.0)

35 (47.3)
39 (52.7)

1.00
1.23 (0.75–2.01)

HR (95% CI)

1

Eyebrow hair DNA positive to any beta HPV type versus negative to all 25 beta HPV types. 2 Eyebrow hair DNA positive to at least one beta 1 HPV type versus
DNA negative to 25 beta HPV types. 3 Eyebrow hair DNA positive to at least one beta 2 HPV type versus DNA negative to 25 beta HPV types. 4 Eyebrow hair
DNA positive to 2 or more beta-1 HPV types versus DNA negative to 25 beta HPV types or positive to one beta 1 HPV type. 5 Eyebrow hair DNA positive to
2 or more beta 2 HPV types versus DNA negative to 25 beta HPV types or positive to one beta 2 HPV type. HR = hazards ratio, CI = confidence interval.
∗
Adjusted for age and gender.

Table 5: Association of beta HPV infection in eyebrow hair and beta HPV seropositivity with the risk of subsequent SCC by index tumor HPV
DNA status.
Viral infection at
the time of index
SCC diagnosis

HPV DNA negative index SCC
No subsequent
Subsequent
HR
SCC (𝑛 = 23)
SCC (𝑛 = 22)
(95% CI)

HPV serology
Any beta 𝐻𝑃𝑉1,3
Beta HPV seronegative

7 (30.4)

10 (45.5)

Beta HPV seropositive

16 (69.6)

12 (54.5)

3 (13.6)

6 (27.3)

19 (86.4)

16 (72.7)

Any beta 1 𝐻𝑃𝑉
DNA negative

3 (25.00)

6 (33.3)

DNA positive

9 (75.0)

12 (66.7)

3 (15.0)

6 (35.3)

17 (85.0)

11 (64.7)

HPV infection in eyebrow hairs
Any beta 𝐻𝑃𝑉2,3
DNA negative to all beta HPV types
DNA positive to ≥1 beta HPV

1.00
0.44
(0.18–1.03)

1.0
0.97
(0.38–2.50)

HPV DNA positive index SCC
No subsequent Subsequent SCC
HR
SCC (𝑛 = 31)
(𝑛 = 55)
(95% CI)

7 (22.6)

12 (21.8)

24 (77.4)

43 (78.9)

2 (6.7)

5 (9.4)

28 (93.3)

48 (90.6)

2 (11.1)

1 (2.8)

16 (88.9)

35 (97.2)

1 (4.8)

5 (12.8)

20 (95.2)

34 (87.2)

1.00
0.92
(0.48–1.75)

1.0
0.30
(0.11–0.78)

4

Any beta 2 𝐻𝑃𝑉4
DNA negative
DNA positive
1

1.0
1.21
(0.45–3.24)
1.0
0.85
(0.31–2.32)

1.0
0.72
(0.09–5.45)
1.0
0.32
(0.12–0.86)

Any beta HPV seropositivity was defined as seropositive to ≥1 beta HPV types versus seronegative to all beta HPV types. 2 Any beta HPV infection in eyebrow
hairs was defined as DNA positivity to ≥1 beta HPV types versus DNA negativity to all beta HPV types. 3 Tumor DNA status was defined as DNA positive
to one or more beta HPV types versus DNA negative to all beta HPV types. 4 Tumor DNA status was defined as DNA positivity to species-specific beta HPV
types versus DNA negative to all beta HPV types.
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SCCs. Thus, acquired immunity through vaccination against
cutaneous HPV could potentially be explored among SCC
cases. Additional strengths of this study include, examination
of biomarkers of both, present HPV infection (eyebrow hair
DNA and HPV serology) and past HPV infection (HPV
serology) and evaluation of HPV infection as a prognostic
marker by HPV genera and species.

4. Conclusion
In conclusion, the results from our prospective cohort study
suggest that cutaneous HPV infection in eyebrow hairs is
inversely associated with the development of subsequent
SCCs in a subset of SCC cases with HPV DNA positive
tumors. The observed association supports previous reports
of lack of a role for cutaneous HPV infection in progression
of SCCs. While cutaneous HPV may not be directly involved
in the prognosis of SCC, this line of research may eventually lead to discovery of underlying immunological factors
involved in SCC development and progression. Cutaneous
HPV infection status could potentially be used as a biomarker
for prognostic stratification of SCCs.
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